Previous 10 | Next 10 |
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C...
2024-03-05 11:25:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the m...
2024-02-25 13:37:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks . Of course, the excitement goes toward both ext...
2024-02-13 14:25:34 ET More on Adicet Bio Adicet Bio: Clinical Updates In H2 2024 Makes This A Must-Watch Adicet Bio announces pricing of public offering Adicet Bio stock rallies 26% on pipeline, cash runway updates Seeking Alpha’s Quant Rating on Adic...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Gug...
2024-01-29 08:28:44 ET Revelation Biosciences ( REVB ) +69% . TuanChe ( TC ) +38% . Spectral AI ( MDAI ) +38% . Hub Cyber Security ( HUBC ) +34% . Cadrenal Therapeutics ( CVKD ) +14% . J-Long Group ( JL ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common st...
2024-01-23 11:08:11 ET More on Adicet Bio Adicet Bio: Clinical Updates In H2 2024 Makes This A Must-Watch Adicet Bio stock rallies 26% on pipeline, cash runway updates Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio ...
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common...
2024-01-22 16:34:40 ET More on Adicet Bio Adicet Bio: Clinical Updates In H2 2024 Makes This A Must-Watch Adicet Bio stock rallies 26% on pipeline, cash runway updates Read the full article on Seeking Alpha For further details see: Adicet Bio stock sinks ...
News, Short Squeeze, Breakout and More Instantly...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferi...